References
- Marsland BJ, Trompette A, Gollwitzer ES. The gut–lung axis in respiratory disease. Annals ATS. 2015; 12(Supplement 2): S150–6.
- Schuijt TJ, Lankelma JM, Scicluna BP, De Sousa E, Melo F, Roelofs JJTH, De Boer JD, Hoogendijk AJ, de Beer R, de Vos A, Belzer C, et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut. 2016; 65(4): 575–83.
- Tulic MK, Piche T, Verhasselt V. Lung–gut cross-talk: Evidence, mechanisms and implications for the mucosal inflammatory diseases. Clin Experimental Allergy. 2016; 46(4): 519–28.
- Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O. The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases. Cellular Microbiology. 2018; 20(12): e12966.
- Zhang M, Zhou Y, Li H, Peng Y, Qiu P, Shi X, et al. COVID-19: Gastrointestinal symptoms from the view of gut–lung axis. European Journal of Gastroenterology & Hepatology. 2021; 33(5): 610–2.
- Nogal P, Wierzbicka M, Zagozda N, Jackowska J. The importance of the gut microbiota in the promotion, development and treatment outcomes of cancer with special regard to the gut-respiratory axis. Otolaryngol Pol. 2022; 76(6): 1–5.
- Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C, Man YG, Chen T. Antibiotics for cancer treatment: A double-edged sword. J Cancer. 2020; 11(17): 5135–49.
- Frankel AE, Deshmukh S, Reddy A, Lightcap J, Hayes M, McClellan S, Singh S, Rabideau B, Glover TG, Roberts B, Koh AY. Cancer immune checkpoint inhibitor therapy and the gut microbiota. Integr Cancer Ther. 2019; 18: 1534735419846379.
- McDonald EG, Milligan J, Frenette C, Lee TC. Continuous proton pump inhibitor therapy and the associated risk of recurrent clostridium difficile Infection. JAMA Intern Med. 2015; 175(5): 784.
- Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol. 2013; 13(11): 790–801.
- Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013; 14(7): 685–90.
- Digomann D, Kurth I, Tyutyunnykova A, Chen O, Löck S, Gorodetska I, Peitzsch C, Skvortsova II, Negro G, Aschenbrenner B, et al. The CD98 heavy chain is a marker and regulator of head and neck squamous cell carcinoma radiosensitivity. Clinical Cancer Research. 2019; 25(10): 3152–63.
- Digomann D, Linge A, Dubrovska A. SLC3A2/CD98hc, autophagy and tumor radioresistance: A link confirmed. Autophagy. 2019 Oct 3; 15(10): 1850–1.
- Ferreira MR, Muls A, Dearnaley DP, Andreyev HJN. Microbiota and radiation-induced bowel toxicity: Lessons from inflammatory bowel disease for the radiation oncologist. The Lancet Oncology. 2014; 15(3): e139–47.
- Jiang C, Wang H, Xia C, Dong Q, Chen E, Qiu Y, Su Y, Xie H, Zeng L, Kuang J, et al. A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma. Cancer. 2019; 125(7): 1081–90.
- Drossman DA, Patrick DL, Whitehead WE, Toner BB, Diamant NE, Hu Y, et al. Further validation of the IBS-QOL: A disease-specific quality-of-life questionnaire. Am J Gastroenterology. 2000r; 95(4): 999–1007.
- Brouwer-Brolsma EM, Berendsen AAM, Sluik D, van de Wiel AM, Raben A, de Vries JHM, Brand-Miller J, Feskens EJM. The Glycaemic Index-Food-Frequency Questionnaire: Development and validation of a food frequency questionnaire designed to estimate the dietary intake of glycaemic index and glycaemic load: An effort by the PREVIEW Consortium. Nutrients. 2018 Dec 20; 11(1): 13.